Business Context and Reporting Period
Company: NeuroPace, Inc. (NPCE)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: NeuroPace is a medical device company focused on treating drug-resistant focal epilepsy with its RNS System, a brain-responsive neuromodulation device. The system monitors brain activity and delivers real-time stimulation to prevent seizures. As of December 31, 2025, over 8,000 patients have received the RNS System. The company is seeking FDA label expansion to include patients with idiopathic generalized epilepsy and pediatric patients (ages 12-17).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $99,986 | $79,906 |
| Gross Profit | $77,220 | $59,085 |
| Gross Margin | 77.2% | 73.9% |
| Operating Loss | $(16,338) | $(21,671) |
| Net Loss | $(21,465) | $(27,141) |
| Cash, Cash Equivalents & Short-Term Investments | $61,100 | $52,755 |
| Long-Term Debt (Net) | $58,884 | $59,525 |
| Accumulated Deficit | $(552,415) | $(530,950) |
Liquidity: The company maintains a minimum liquidity covenant of $25.0 million under its MidCap Term Loan. As of December 31, 2025, total liquidity (cash, cash equivalents, and short-term investments) was $61.1 million, exceeding the covenant requirement.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 25% to $100.0 million, driven by higher RNS System unit sales, DIXI Medical product sales, and service revenue. DIXI Medical products represented approximately 16% of total revenue in 2025.
- Debt Restructuring: In June 2025, the company repaid its CRG Term Loan (approx. $61.9 million) and entered into a new $60.0 million MidCap Term Loan with a maturity date of June 4, 2030. This reduced the annual effective interest rate compared to the previous facility.
- Equity Transactions: In February 2025, the company completed a follow-on offering raising $69.7 million in net proceeds. $49.5 million of these proceeds were used to repurchase all shares held by significant stockholder KCK Ltd.
- Partnership Termination: The exclusive distribution agreement with DIXI Medical expired on September 30, 2025, with a wind-down period concluding on December 31, 2025. Future revenue will no longer include DIXI product sales.
- Profitability: Net loss improved by 21% to $21.5 million, primarily due to revenue growth and lower interest expense following the debt refinancing.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Commercial Expansion: The company is expanding sales efforts beyond Level 4 Comprehensive Epilepsy Centers (CECs) to community-based epileptologists and neurosurgeons following a 2023 FDA PMA-S approval.
- Label Expansion: A PMA-S was filed in December 2025 to expand indications to patients with drug-resistant idiopathic generalized epilepsy (IGE), supported by preliminary NAUTILUS study data showing 77% median seizure reduction. Pediatric label expansion efforts (ages 12-17) are ongoing via the RESPONSE study and a collaboration with NEST.
- International: Limited sales have commenced in Israel; the company is evaluating further international expansion.
Key Risks and Contingencies:
- Regulatory Approval: Failure to obtain FDA approval for expanded indications (IGE and pediatric) could materially harm growth potential.
- Debt Covenants: The MidCap Term Loan contains financial maintenance covenants, including minimum liquidity and quarterly revenue thresholds. Failure to comply could trigger an event of default.
- Supply Chain: Reliance on single-source suppliers for critical components (e.g., batteries, printed circuit assemblies) creates vulnerability to supply shortages.
- Reimbursement: Changes in third-party payor coverage or reimbursement rates could negatively impact sales.
- Profitability: The company expects to continue incurring net losses for the foreseeable future and may require additional capital.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to maintain the $25.0 million minimum liquidity and meet quarterly revenue covenants under the MidCap Term Loan.
- Revenue Mix Transition: Monitor the impact of the DIXI Medical distribution agreement expiration on future revenue growth and gross margin stability.
- Regulatory Milestones: Track the FDA review timeline and decision on the December 2025 PMA-S filing for idiopathic generalized epilepsy and the progress of pediatric studies.
- Cash Burn Rate: Assess the runway provided by the $61.1 million cash balance against operating expenses and capital requirements for clinical trials and commercial expansion.
- Supply Chain Resilience: Evaluate the status of single-source supplier relationships and any contingency plans for critical component shortages.